At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02575 XUANZHUBIO-B
Not Yet Opened 05-13 16:08:10
19.880
-2.120
-9.64%
High23.380Low19.800Vol1.94M
Open21.400D1 Closing22.000Amplitude16.27%
Mkt Cap10.30BTradable Cap3.19BTotal Shares518.00M
T/O39.49MT/O Rate1.21%Tradable Shares160.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%
Bulletin Express  ·  05-12 19:02
Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%
Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares
Bulletin Express  ·  05-12 17:03
Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares
XUANZHUBIO-B Completes Full Circulation of H Shares
Stock News  ·  05-12 16:34
XUANZHUBIO-B Completes Full Circulation of H Shares
Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares
Reuters  ·  05-12 16:31
Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares
Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation
Simply Wall St.  ·  05-06
Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation
XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects
Stock News  ·  04-28
XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects
Xuanzhu Biopharm initiates full electronic delivery of shareholder communications; urges investors to submit email contacts
Bulletin Express  ·  04-27
Xuanzhu Biopharm initiates full electronic delivery of shareholder communications; urges investors to submit email contacts
玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局
Bulletin Express  ·  04-27
玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局
Xuanzhu Biopharmaceutical publishes inaugural 2025 ESG report; R&D spend reaches RMB 183.84 million and Scope 1-2 emissions total 1,237 tCO₂e
Bulletin Express  ·  04-27
Xuanzhu Biopharmaceutical publishes inaugural 2025 ESG report; R&D spend reaches RMB 183.84 million and Scope 1-2 emissions total 1,237 tCO₂e
Hong Kong Market Midday Update: Hang Seng Index Drops 1.12% in Morning Session, Coal Stocks Buck the Trend
Stock News  ·  04-23
Hong Kong Market Midday Update: Hang Seng Index Drops 1.12% in Morning Session, Coal Stocks Buck the Trend
Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR
Stock News  ·  04-23
Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR
SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR
Stock News  ·  04-21
SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR
CATL Shareholder Sets A-Share Transfer Price at 410.34 Yuan; Nitrogen Fertilizer Prices May Climb Further
Stock News  ·  04-21
CATL Shareholder Sets A-Share Transfer Price at 410.34 Yuan; Nitrogen Fertilizer Prices May Climb Further
Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026
Bulletin Express  ·  04-20
Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026
Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate
Reuters  ·  04-20
Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate
XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR
Stock News  ·  04-19
XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR
Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%
Reuters  ·  04-19
Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%
Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares
Bulletin Express  ·  04-17
Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares
XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan
Stock News  ·  04-17
XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan
Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares
Reuters  ·  04-17
Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares

Introduction

Company Name.
XUANZHUBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.
Issue price:
--